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Abstract  
1. Metabolic acidosis due to accumulation of L-5-oxoproline is a rare, poorly understood, disorder 
associated with acetaminophen treatment in malnourished patients with chronic morbidity. L-5-
oxoprolinuria signals abnormal functioning of the γ-glutamyl cycle which recycles and synthesises 
glutathione. Inhibition of glutathione synthetase (GS) by N-acetyl-p-benzoquinone imine (NAPQI) could 
contribute to 5-oxoprolinuric acidosis in such patients. We investigated the interaction of NAPQI with GS in 
vitro. 
2. Peptide mapping of co-incubated NAPQI and GS using mass spectrometry demonstrated binding of 
NAPQI with cysteine-422 of GS which is known to be essential for GS activity. Computational docking shows 
that NAPQI is properly positioned for covalent bonding with cysteine-422 via Michael addition and hence 
supports adduct formation. 
3. Co-incubation of 0.77 µM of GS with NAPQI (25 to 400 µM) decreased enzyme activity by 16% to 89%. 
Inhibition correlated strongly with the concentration of NAPQI and was irreversible. 
4. NAPQI binds covalently to GS causing irreversible enzyme inhibition in vitro. This is an important novel 
biochemical observation. It is the first indication that NAPQI may inhibit glutathione synthesis, which is 
pivotal in NAPQI detoxification. Further studies are required to investigate its biological significance and its 
role in 5-oxoprolinuric acidosis.  
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Introduction  
High anion gap metabolic acidosis (HAGMA) due to accumulation of L-5-oxoproline (pyroglutamic acid) is a 
rare, serious, biochemical disturbance which has been attributed to treatment with acetaminophen. It 
develops acutely in patients receiving regular treatment with the drug, generally in therapeutic doses and 
with non-toxic plasma concentrations. The disturbance usually resolves within days of acetaminophen 
withdrawal and seldom recurs. Among 50 patients reported to 2014 (Abkur et al., 2014; Brohan et al., 2014; 
Liss et al., 2013; Pitt and Hauser, 1998) the majority were poorly nourished, had one or more chronic 
morbidities requiring pain relief, and often on-going sepsis. Some were alcohol abusers, had renal 
impairment, and/or post-operative infection and three were pregnant. The median age was 54 y (range 1-
84 y) and 84 % were women. None had a reported relevant family history. The diagnosis is made by analysis 
of organic acids in blood and/or urine by specialist paediatric metabolic laboratories. Because these tests 
are not routinely available, and few adult clinicians are aware of them, the condition has almost certainly 
been under-diagnosed (Emmett, 2014; Liss et al., 2013; Pitt and Hauser, 1998). 5-Oxoprolinuria was only 
introduced into diagnostic mnemonics for HAGMA in 2008 (Mehta et al., 2008).  
Evidence supporting an association with acetaminophen is the observation that rats treated chronically 
with 1 mmol of acetaminophen daily develop progressive 5-oxoprolinuria after three weeks (Ghauri et al., 
1993). Further, human hepatocytes transfected with cytochrome P450 2E1 produce large amounts of 5-
oxoproline when exposed to acetaminophen (Geenen et al., 2011; Geenen et al., 2013). However, the 
mechanisms leading to 5-oxoprolinuria are poorly understood. 
L-5-oxoproline is generated endogenously by the action of γ-glutamyl cyclotransferase (γ-GCT) on γ-
glutamyl amino acids, and of γ-glutamylamine cyclotransferase (γ-GACT) on γ-glutamyl amines. These 
include γ-glutamyl-ϵ-lysine released during degradation of fibrin and other proteins cross-linked by 
transglutaminase (Oakley et al., 2010; Williamson and Meister, 1982). In addition, it is a by-product of 
glutathione synthesis and is also released from modified terminal amino acids of peptides and proteins. 5-
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Oxoproline is hydrolysed to L-glutamate by 5-oxoprolinase. γ-GCT, γ-GACT and 5-oxoprolinase are 
constituents of the γ-glutamyl cycle (Larsson and Anderson, 2005) which co-ordinates the activities of the 
enzymes involved in glutathione catabolism and the two required for glutathione synthesis (glutathione 
synthetase (GS) and γ-glutamylcysteine synthetase  (γ-GCS; γ-glutamylcysteine ligase). γ-GCS is rate-limiting 
for the cycle and is regulated by glutathione through feedback inhibition (Figure 1a).     
Figure 1. 5-Oxoproline metabolism via the γ-glutamyl cycle (a) with normal GS activity; (b) with genetic GS 
deficiency. γ-GCS = γ-glutamylcysteine synthetase; GS = glutathione synthetase; γ-GCT = γ-glutamyl 
cyclotransferase; γ-GACT= γ-glutamylamine cyclotransferase. 
Figure 1a 
 
Figure 1b 
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Significant accumulation of L-5-oxoproline occurs rarely and indicates a mismatch between L-5-oxoproline 
production and its degradation. This occurs in two very rare inherited enzyme disorders of the γ-glutamyl 
cycle with low activities of either GS or 5-oxoprolinase (Njålsson et al., 2005; Ristoff and Larsson, 2007). In 
GS deficiency, intracellular glutathione is reduced to 5% to 21%. Inhibition of γ-GCS is lifted, and excessive 
amounts of γ-glutamylcysteine are synthesised and diverted to 5-oxoproline, overwhelming the capacity of 
5-oxoprolinase (Figure 1b). Individuals with moderate or severe forms of the disorder present neonatally or 
in early infancy with metabolic acidosis and haemolytic anaemia (Njålsson et al., 2005). In 5-oxoprolinase 
deficiency, there is massive L-5-oxoprolinuria, but no acidosis, glutathione deficiency or haemolysis 
(Larsson and Anderson, 2005; Ristoff and Larsson, 2007). A significant proportion of the L-5-oxoproline in 
this disorder probably derives from renal metabolism.  
There is no published evidence that any of the reported patients with 5-oxoprolinuric HAGMA had either of 
these inherited defects. However, they are likely to have had low glutathione reserves because of their 
chronic morbidity, and hence increased γ-glutamylcysteine production. Glutathione depletion also reduces 
the capacity to detoxify N-acetyl-p-benzoquinone imine (NAPQI), the toxic metabolite of acetaminophen 
(Bessems and Vermeulen, 2001; Cohen and Khairallah, 1997; Mitchell et al., 1973). Pitt & Hauser (1998) 
suggested that in such patients GS becomes rate limiting or is inhibited, leading to ƴ-glutamylcysteine 
accumulation.  
NAPQI is a highly reactive electrophile which forms adducts selectively with liver proteins, most often by 
reaction with cysteine residues (Bessems and Vermeulen, 2001; Chen at al., 1999; Cohen and Khairallah, 
1997). Twenty nine proteins which bind NAPQI have been identified (Dietze et al., 1997; Qiu et al., 1998). In 
the majority, the functional effects of binding were not investigated. However, NAPQI binding has been 
associated with reduced activity of seven hepatic enzymes (glutamine synthetase (Bulera et al., 1995; 
Gupta et al., 1997), glutamate dehydrogenase (Halmes et al., 1996), mitochondrial aldehyde 
dehydrogenase (Landin et al., 1996), glyceraldehyde-3-phosphate dehydrogenase (Dietze et al., 1997), N-
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10-formyl-tetrahydrofolate dehydrogenase (Pumford et al., 1997), carbamyl phosphate synthetase-1 
(Gupta et al., 1997), and glutathione  S-transferase pi (Jenkins et al., 2008). Although not previously 
reported to form a NAPQI adduct, human GS has three cysteine residues C294, C409 and C422 (Gali and 
Board, 1995) and is a potential candidate for NAPQI binding. C422 is essential for enzyme activity (Gali and 
Board, 1997).  
We investigated the interaction of NAPQI with GS in vitro in order to ascertain whether inhibition of GS 
could be a tenable explanation for acetaminophen associated 5-oxoprolinuric HAGMA. 
 
Materials and methods 
Chemicals 
N-terminal His-tagged recombinant human GS (hGS) expressed in E. coli (purity > 95% by SDS-PAGE) used in 
the NAPQI/GS binding studies was from Novus Biologicals Ltd. (Cambridge, UK). His-tagged recombinant 
hGS used in the enzyme kinetic studies was expressed in E. coli and purified as reported previously (~105 
kDa; purity > 99% by SDS-PAGE (Dinescu et al., 2004)). L-γ-glutamyl-L-α-aminobutyric acid (GAB) > 90% pure 
was custom-made by Peptide Protein Research Ltd. (Fareham, UK). NAPQI was from Dalta Pharma Services 
(Toronto, Canada). Phospho(enol) pyruvic acid monosodium salt (97% pure), lactate dehydrogenase from 
rabbit muscle type II, pyruvate kinase from rabbit muscle type III, adenosine 5'-triphosphate disodium salt 
hydrate, reduced nicotinamide adenine dinucleotide disodium salt, Trisma hydrochloride (Tris-HCl) and all 
other chemical reagents were from Sigma-Aldrich (Poole, UK). 
NAPQI/GS binding studies 
A previously published procedure (Parkinson et al., 2014) was modified to analyse NAPQI/GS adducts. From 
preliminary studies, 5 μg (0.048 nmol) of enzyme was the smallest amount of enzyme needed to produce 
informative spectra of the modified peptide. 5 μL of GS (1 g/L in 100 mM ammonium bicarbonate pH 8.0) 
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was added to 5-50 μL of NAPQI (1 g/L in 5% acetonitrile/ammonium bicarbonate) and incubated at 37ºC for 
1 h. The reaction mixture was lyophylised using a centrifugal evaporator, and resuspended in 15 μL of 
NuPAGE LDS sample buffer without dithiothreitol (Novex; Life Technologies, Paisley, UK). The enzyme was 
separated by electrophoresis at 200 mV for approximately 45 min using a Nu-Page 4-12% Bis-Tris gel 
(Novex; Life Technologies) with unmodified GS as a control. Following staining with Coomassie Blue, the 
protein band was excised and in-gel digestion undertaken as described by Shevchenko et al. (1996). Peptide 
extracts containing 500-1000 ng of peptide were resuspended in solvent A (0.1% formic acid in water (v/v)), 
loaded onto a reversed-phase trap column (Xbridge BEH C18 NanoEase column, 5 μm particle size, 300 μm x 
50 mm (Waters; Elstree, UK) at a trapping flow rate of 5 μL/min, and washed for 10 min with solvent A prior 
to analytical separation using a C18 reversed-phase column (BEH C18, 1.7 μm particle size, 75 μm x 150 mm, 
Waters). The peptides were eluted over a 37 min continuous gradient from 1% acetonitrile/0.1% formic 
acid up to 80% solvent B (acetonitrile/0.1% formic acid), at a flow rate of 300 nL /min. The eluates were 
sprayed directly into a G2-S Synapt Q-ToF mass spectrometer (Waters, Manchester, UK) fitted with a nano-
lockspray source and operating using the data independent mode of acquisition, MSE. Data were acquired 
from m/z = 50-1990 using alternate low and elevated collision energy (CE) scans with the low collision 
energy set to 5 V and an elevated collisional energy ramp from 15-40 V. The lock mass Glu-fibrinopeptide, 
m/z = 785.8426 (M+2H)2+ was infused at a concentration of 100 fmol/μL with a flow rate of 300 nL/min and 
data acquired every 60 s. The raw mass spectra were processed using ProteinLynx Global Server Version 2.4 
(Waters) and the processed data were used to generate reduced charge state and deisotoped precursor 
and associated product ion peak lists. These peak lists were searched against the human database 
(obtained from UniProt 01/2013). A maximum of one missed cleavage was allowed for tryptic digestion and 
the variable modification was set to contain oxidation of methionine, carboxyamidomethylation of 
cysteine, deamidation of glutamine and asparagine and NAPQI modification of cysteine. Searches were 
performed with a false positive rate set at 2%. 
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Analysis of GS activity 
hGS was reconstituted in 10 mM Tris-HCl buffer pH 8.2 (protein concentration 162 mg/L) and stored at 4 ºC. 
GS activity was measured at 37 ºC using a published spectrophotometric procedure (Dinescu et al., 2004) 
adapted for use on a Konelab 20 spectrophotometric analyser (Labmedics; Manchester, UK). This 
procedure couples ADP production from ATP during the GS reaction to NADH oxidation by a reporter 
enzyme system [phospho(enol) pyruvate (PEP), pyruvate kinase (PK), lactate dehydrogenase (LDH) and 
reduced NAD (NADH)]. Oxidation of NADH was monitored at 340 nm. Because the natural enzyme 
substrate γ-glutamylcysteine would conjugate with NAPQI, the synthetic dipeptide GAB was used as an 
alternative. GS activity is the same with both substrates (Oppenheimer et al., 1979). In brief, for a final 
volume of 200 μL per test sample, 10 μL of GS, GS/NAPQI co-incubate or water was added to a pre-warmed 
mixture of assay buffer (100 mM Tris-Cl buffer pH 8.2, 50 mM KCl, 20 mM MgCl2), 0.34 mM NADH2, 10 mM 
glycine, 10 mM GAB, 10 mM ATP, 5 mM PEP, 10 units of PK, and 4 units of LDH. Absorbance at 340 nm was 
measured at 28 s intervals for 168 s (7 recordings). One unit of GS activity was defined as the amount of GS 
that catalysed 1 μmol of product formation/min (i.e. NADH oxidized/min) at 37ºC. 
                                                                                                                                                                                                                                  
NAPQI/GS co-incubation 
Five mg of NAPQI in 672 μL acetonitrile (50 mM NAPQI) was diluted freshly in water to concentrations of 
50-2000 μM. The solutions were kept on water ice, protected from light. Equal volumes of diluted NAPQI 
and GS (130 mg/L in preliminary experiments and 162 mg/L subsequently), were mixed, co-incubated at 37 
ºC for 28 min, cooled rapidly in water ice and transferred to the spectrophotometer to be sampled. The 
enzyme reaction was started exactly 30 min after the commencement of co-incubation. 
.                                                                                                                                                                                 
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Effect of NAPQI on the coupled reporter system used to measure GS activity 
Possible inhibition/inactivation of one or more components of the reporter pathway was investigated in 
two experiments by monitoring the change in absorbance at 340 nm after adding ADP as substrate to the 
reporter system in the presence or absence of NAPQI. 
Experiment 1: Ten μL of water (control) or 10 μL of 200 μM NAPQI (test)  was equilibrated at 37 ºC with the 
routine assay mixture containing all the components of the reporter system but without addition of GAB, 
ATP or GS. After recording baseline absorbance, 10 μL of water (control) or 0.84 mM ADP was added to 
start the enzyme reaction sequence. The absorbance was recorded again at 1 min. 
Experiment 2: The effects of NAPQI on the activity of the full reporter system (PK, LDH and NADH) and on 
NADH alone were investigated. By comparison, it was possible to differentiate effects of NAPQI on NADH 
from those on PK + LDH. Ten μL of water, 200 μM or 400 μM of NAPQI were equilibrated at 37 ºC for 3 min 
with the routine assay mix containing all the reporter system components (PEP, PK, LDH and NADH ) but 
without  GAB, ATP and GS (series a), or containing only PEP and NADH (series b). After recording baseline 
absorbance, 10 μL of 0.84 mM ADP or water was added to start the reaction and the absorbance was 
recorded again at 1 min. 
The possibility that doubling the amounts of PK and LDH in the standard GS assay might restore activity of 
GS co-incubated with NAPQI was also investigated.  After pre-incubating water or NAPQI (200 μM) with GS 
for 30 min at 37 ºC, 10 uL was transferred to the standard assay mixture, but with addition of normal or 
twice the normal amounts of PK or LDH. GS activity was measured by the standard procedure.  
Protein concentration 
GS protein was analysed with an automated pyrogallol red/molybdate procedure calibrated with human 
serum albumin (Beckman Coulter Inc., High Wycombe, UK). 
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Computations  
Kinetic data were recorded and plotted in Excel (Microsoft Office Word, 2007). Km and Vmax were calculated 
using non-linear regression (curve fit) enzyme kinetics programs of Graph Pad Prism 5 version 5.04 
(GraphPad; La Jolla, CA, USA). Graph Pad Prism was used for statistical analyses. Statistical significance was 
< 0.05. 
Computer modeling of NAPQI interaction with hGS  
Utilizing the crystal structure of hGS (PDB ID = HGS) as a starting structure, a molecular dynamics (MD) 
simulation of free dimeric wild-type hGS (Polekhina et al., 1999) was conducted. GROMACS was used for 
the 10 ns run with the AMBER99sb force field and the simple point charge water model, as described in 
previous work (Berendsen et al., 1981; Cornell et al., 1995; De Jesus et al., 2014; Hess et al, 2008; Hornak et 
al., 2006; Wang et al., 2000). The lowest energy frame was then extracted from the last ns of the simulation 
for further analysis. The structure of NAPQI was optimised in Gaussian ’09 with the B3LYP functional and 6-
31+G(d) basis set (Andersson and Uvdal, 2005; Becke, 1988; Becke, 1993; Stephens et al., 1994). The 
Molecular Operating Environment (MOE) 2013.08 software (Chemical Computing Group Inc.; Montreal, 
Canada, 2014) was then used to dock NAPQI near C409 and C422 with an AMBER99 force field (Cornell et 
al., 1995; Molecular Operating Environment, 2014; Wang et al., 2000). The induced fit docking method was 
coupled with the London and GBVI/WSA scoring functions (Corbeil et al., 2012; Labute, 2008).        
Results 
Binding of NAPQI to GS                                                                                                                                                              
NAPQI binding studies confidently identified a single modified peptide (419 to 434). This 16 amino acid 
sequence (VVQCISELGIFGVYVR) had a molecular mass (1989 Da) consistent with deamidation at position 
421, carboamidomethylation and modification by NAPQI (Appendix 1, Figure 5, a to d). Fragmentation mass 
spectra were unable to isolate the exact amino site of modification, but could pinpoint the modifications to 
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within the amino acids 421-423 (Gln, Cys, Ile). In light of the excess iodoacetamide used to block the 
remaining cysteine residues after reaction and removal of excess NAPQI, it is probable that the deamidated 
glutamine residue (421) was carboamidomethylated and Cys 422 modified by NAPQI. The modified peptide 
was observed in two independent experiments, but not in control samples incubated in the absence of 
NAPQI. The analytical procedure provided good coverage of the GS protein, with > 80% of the peptides 
consistently matched correctly with the primary amino acid sequence of the protein. Peptide modification 
was evident with mixtures of 5 μg (0.048 nmol) of GS and 5 μg (33.6 nmol) of NAPQI. However, the mass 
spectrometer signals were more intense with a higher NAPQI concentration and spectral quality was 
improved at 15 μg.                                                                                                              
Activity of GS  
Activity of GS without NAPQI 
GS is an allosteric enzyme with two identical subunits which show negative cooperativity to the γ-glutamyl 
substrate: the affinity of GS for this substrate falls with increased availability of γ- glutamyl substrate 
(Dinescu et al., 2004; Luo et al., 2000; Njalsson et al., 2001; Oppenheimer et al., 1979). Because we worked 
with high GAB substrate concentrations, we only observed activity at the high Km:  double reciprocal plots 
of substrate concentration versus enzyme activity were linear. From two experiments, with GAB 
concentrations ranging from 0.625 mM to 10 mM the calculated Km (95% confidence intervals, CI) was 1.12 
(0.95, 1.30) mM and 1.22 (0.89, 1.55) mM, Vmax was 7.75 (7.41, 8.09) and 7.89 (7.26, 8.52) μmol/mg/min 
and kcat was 13.6 (13.0, 14.2) and 13.8 (12.7, 14.9) s
-1. Others, who extended their observations to lower, 
more physiological, substrate concentrations (< 0.4 mM) found non-linear plots indicative of allosteric 
activity, and estimated separate approximate Km values for the active sites of the enzyme (Luo et al., 2000; 
Njalsson et al., 2001; Oppenheimer et al., 1979). Our Km is higher than estimates for the initial Km for a 
comparable GS preparation and assay, but similar to Km estimates for the second binding site (Km2 = 1.50 
mM; Dinescu et al., 2004),   and to a reported value of 0.99+/-0.07 mM reported for GS purified from 
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human blood haemolysates (Njålsson et al., 2000). Kcat was higher than a value of 6.5 s
-1 reported for a 
similar GS preparation analysed with 20 mM GAB as substrate at pH 8.2 (Dinescu et al., 2004), and closer to 
a more recently reported value of 19.5 s-1 (Slavens et al., 2011). The enzyme was stable for at least 7 days 
after reconstitution. 
Activity of glutathione synthetase co-incubated with NAPQI     
NAPQI was pre-incubated in concentrations ranging from 25 to 400 μM with 81 mg/L (0.77 μM; two 
experiments) or 65 mg/L (0.62 μM; one experiment) of GS at for 30 min at 37 ºC. Residual enzyme activity 
was measured with GAB substrate concentrations ranging from 0.625 mM to 10 mM.  Figures 2a and 2b 
show the results for one experiment in which the full range of NAPQI concentrations was investigated at 
five concentrations of GAB. Similar results were obtained in a second experiment which examined the 
effects of NAPQI at the lower end of the range (0 to 100 μM) with GAB concentrations of 2.5 mM and 10 
mM (Appendix 2, Figures 6a and 6b).  
Figure 2.  Inhibition of activity of GS (81 mg/L; 0.77 μM) pre-incubated with NAPQI (0-400 μM) for 30 min at 
37ºC. Enzyme activity was measured by the described procedure, with GAB substrate concentrations 
ranging from 0.625 mM to 10 mM.  NAP = NAPQI; concentrations 0-400 μM.                                
Figure 2a: GS activity, reported as μmol of NADH oxidized in the reporter reaction/min/mg of GS;  
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Figure 2b: time course of GS activity after 30 min of preincubation of NAPQI with GS. GS activity was 
monitored at 28 s intervals for 168 s under standard assay conditions with 10 mM GAB as substrate. 
Activity reported as μmol of NADH oxidized/mg of GS. 
 
As shown in Figures 2a and 2b, pre-incubation with NAPQI decreased GS activity and the enzyme inhibition 
was dose-dependent. The residual activity of GS pre-incubated with NAPQI was calculated as a percentage 
of uninhibited activity (pre-incubation without NAPQI) at each concentration of GAB used in the enzyme 
assay. The combined results of all three experiments undertaken showed a highly significant inverse 
correlation between the NAPQI concentration and the residual activity (Spearman correlation coefficient r = 
- 0.98 (95% CI - 0.99, - 0.96, n= 38, P < 0.001). Increasing the concentration of GAB used as substrate in the 
GS assay did not reverse the enzyme inhibition caused by pre-incubation with NAPQI. In the most 
comprehensive experiment (Figure 2), the median (range) of residual GS activity for five concentrations of 
GAB was: 83.2% (82.1-85.1%) with 25 μM NAPQI; 56.0 % (53.7-63.0%) with 100 μM NAPQI; 38.2% (35.4-
45.2%) with 200 μM NAPQI and 10.8% (8.0-16.4%) with 400 μM NAPQI. The ratio of μmol of NAPQI to μmol 
GS in the co-incubates ranged from approximately 30:1 with 25 μM NAPQI to 500:1 with 400 μM NAPQI. 
Comparison of residual GS activity with different concentrations of NAPQI and GAB using the one-way 
Anova test confirmed a lack of association between residual enzyme activity and substrate concentration 
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(Kruskal-Wallis statistic Kw = 0.97, P = 0.965, n = 38, 6 groups; combined results from all three experiments). 
These findings indicate that NAPQI inhibits GS irreversibly.  
Effect of NAPQI on the coupled reporter system used to measure GS activity  
NAPQI is reduced to acetaminophen by NAD(P)H by direct chemical reaction (Dahlin et al., 1984). Oxidation 
of large amounts of NADH by interaction with NAPQI might deplete NADH in the reporter system and 
produce spuriously low results for GS activity. This was investigated, as well as the possibility that NAPQI 
might inhibit PK and LDH used in the coupled reporter system. However, this seemed unlikely since, despite 
the large abundance of these enzymes in liver, to date they have not been reported to form adducts with 
NAPQI. 
In the first experiment to investigate these issues, there was no difference in the change in absorbance 
after adding ADP as substrate to the reporter system incubated without NAPQI (-0.195 units/min) or with 
10 μL of 200 μM NAPQI for 8 min (-0.196 units/min) or 38 min (-0.195 units/min). However, NAPQI reduced 
the baseline absorbance, prior to adding ADP, by 6% and 5% respectively. It was possible that this was due 
to oxidation of NADH by NAPQI. This would only be relevant to the the GS analyses if it occurred very 
rapidly because, in the standard procedure, NADH and the reporter enzymes were not exposed to NAPQI 
until GS/NAPQI co-incubates were added to the assay mix to start the GS reaction.  
The second experiment investigated the effects of exposure to high concentrations of NAPQI for 3 min on 
the activity of the full reporter system (PEP, PK, LDH and NADH) with ADP as substrate and on NADH 
without PK and LDH. From our other studies, pre-incubation of GS with NAPQI at these concentrations 
reduced measured GS activity by around 65% and 89%, respectively. From Table 1 it is clear that NAPQI did 
not inhibit the reporter reaction under the assay conditions. With the complete reporter system, NAPQI 
actually increased the rate of fall of absorbance. This was explained by chemical oxidation of NADH by 
NAPQI (see series (b)) which, however, was insufficient to limit the activity of LDH. In a follow-up 
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experiment addition of 10 μL of 400 μM NAPQI to NADH in assay buffer without ADP or the reporter 
enzymes led to an immediate small initial decrease in absorbance at 340 nm (2%), followed by a gradual 
increase back towards the baseline value.   
Table 1.  Effects of NAPQI on the reporter enzyme system in the glutathione synthetase assay. Oxidation of 
NADH with the full reporter system (PEP, NADH, PK, LDH) and the incomplete system (PEP and NADH only) 
with and without NAPQI was measured by the decrease in absorbance at 340 nm one min after addition of 
0.84 mM ADP as substrate; †10 μL NAPQI added to 190 μL of assay mix. 
NAPQI            
μmol/L† 
Full reporter 
system: PEP, 
NADH, PK, LDH 
                                                                                      
Decrease in 
absorbance (a) 
(units/min) 
Incomplete 
reporter  system: 
PEP, NADH ; no 
PK or LDH                                
Decrease in 
absorbance (b) 
(units/min) 
Decrease in 
absorbance due 
to PK + LDH 
activity 
 
 (a-b) 
 (units/min) 
Decrease in 
absorbance not 
due to PK + LDH 
activity                           
 
(b/a x100)  
(%) 
0 -0.197 -0.004 -0.193 2.0% 
200 -0.212 -0.021 -0.191 9.9% 
400 -0.225 -0.034 -0.191 15.1% 
 
For supportive evidence that NAPQI did not inhibit PK or LDH, the effect of increasing the amounts of PK 
and LDH in the standard GS assay procedure was investigated. Doubling the amounts of reporter enzymes 
had no effect on the measured activity of GS pre-incubated with NAPQI. The mean (range) of GS activities 
(μmol/mg/min) of four replicates for each experimental condition were: normal versus double PK/LDH: 
without NAPQI: 6.7 (6.7-7.1) versus 6.7 (6.7-6.7); with 200 μM NAPQI: 2.4 (2.0-2.8) versus 2.4 (2.0-2.8). 
Collectively, the findings show that under the assay conditions used, NAPQI added in concentrations up to 
400 μM did not inhibit PK or LDH. At the higher concentrations it probably oxidised NADH to a small extent 
but this did not limit the reporter reaction. It might have caused a small spurious increase in measured GS 
activity, but not a decrease. Thus the assay was valid. 
Computer modeling 
A preliminary docking study of NAPQI into a low energy structure of free hGS indicated that C422 was a 
better binding site than C409 (Figure 3). The Michael acceptor of NAPQI (C4’) bound 4.3-10.2 Å from the 
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C409 sulphur. The poses near C409 exhibited a high variation in orientation with several poses on the 
exterior of the protein, indicating that C409 was not an ideal binding site for NAPQI. In contrast, all poses 
near C422 nestled deeply into the binding pocket with the Michael acceptor on NAPQI 3.0-3.8 Å from the 
C422 sulphur. 
Figure 3.  Docked poses near C409 and C422 show the specificity of the C422 binding site, relative to the 
non-specific binding near C409. 
 
The binding site near C422 was between the anti-parallel ß-sheets at the C terminus of hGS (Fig. 4). 
The two dominate binding orientations at C422 had equivalent Michael acceptor positions. The ring of both 
orientations bound in the same position, but the acetamide side chains pointed in opposite directions. In 
both poses the ring of NAPQI was centred above the S of C422 with the guanidyl of R418 and the isopropyl 
of L410 on the opposite side of the ring. In the first group of poses, the acetamide of NAPQI pointed into 
the pocket near S55, N408, and T41. The acetamide of NAPQI pointed towards V420 and the surface of the 
protein in the second type of pose. Computational models of hGS indicated that while NAPQI did not 
exhibit specific binding near C409, NAPQI was  properly positioned for covalent bonding with C422 via 
Michael addition by either dominate binding orientation. 
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Figure 4.  NAPQI binding near Cys422 of hGS. Backbone of hGS shown in ribbon format with relevant 
residues shown as sticks. Representative poses of NAPQI shown in green and purple.  
 
4. Discussion 
Glutathione has an essential role in detoxifying NAPQI (Bessems and Vermeulen, 2001; Geenen et al., 2013; 
Mitchell et al., 1973). Despite this, the possibility that NAPQI might inhibit glutathione synthesis, and thus 
reduce the protection against toxicity, has not been explored.  Pitt and Hauser (1998) suggested that 
inhibition of GS might contribute to the development of acetaminophen-associated 5-oxoprolinuric 
acidosis. We investigated the interaction of NAPQI with GS in vitro in order to ascertain whether this could 
be a tenable explanation. The findings demonstrated clearly that NAPQI binds covalently to GS causing 
irreversible inhibition of enzyme activity. This is a novel biochemical observation. 
Peptides produced by trypsin digestion of the enzyme were analysed in order to identify NAPQI-modified 
amino acids using mass spectrometry, as reported for studies of other liver proteins (Dietze et al., 1997; Qiu 
et al, 1998). NAPQI was shown to bind irreversibly to C422, the cysteine residue which is essential for GS 
activity (Gali and Board, 1997). This could result from a Michael-type addition reaction to the cysteinyl SH 
group to form a C-4' thiohemiketal followed by aromatisation to 3'-proteinS-acetaminophen. Alternatively, 
the cysteinyl SH could be added  to the imine double bond at C1 of NAPQI, forming  an ipso adduct which 
then rearranges to 2'-proteinS-acetaminophen (Bessems and Vermeulen, 2001; Chen et al., 1999; Dietze et 
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al., 1997). Human GS has two identical subunits, each with a central active site surrounded by mobile loops 
that control activity and bind the substrates (Dinescu et al., 2007; Gali and Board, 1995; Polekhina et al., 
1999). While C422 is not directly involved with the active site, it is located within a mini-barrel which 
contributes one wall to the ATP-binding site and it may have a structural role (Polekhina et al., 1999). The 
modeling studies showed that NAPQI can nestle deeply in the molecular pocket containing C422. Covalent 
binding of NAPQI at this site might interfere with catalytic loop motions and block the active site, thus 
reducing GS activity. 
NAPQI was shown to inhibit GS in vitro through an irreversible interaction. From the combined results of 
three experiments, NAPQI in concentrations ranging from 25 μM to 400 μM inhibited the activity of 81 
mg/L (0.77 μM) of GS by 16 % to 89%. Inhibition was significantly dose-related. Other proteins and 
glutathione were not included in the assays, and we do not know whether these concentrations are 
biologically relevant. The amount of free NAPQI in hepatocytes cannot be quantified directly because of its 
reactivity. Exposure of mouse hepatocytes in vitro to 250 μM and 500 μM of NAPQI, but not to 100 μM, 
caused toxic changes (cell surface blebs) (Moore et al., 1985). Intracellular concentrations are probably 
much lower in vivo. Protein derived acetaminophen (APAP)-cysteine is measured in plasma as an indicator 
of the amount of NAPQI-protein adduct formed in liver. Plasma concentrations range from <1 to 27 μM 
after overdose (Heard et al., 2011; Muldrew et al., 2002; McGill et al., 2013). However, these probably 
under-estimate the liver concentrations. In experimental animals given acetaminophen, damage to the liver 
by ischaemia/reperfusion increased blood levels of APAP-cysteine significantly (McGill et al., 2013).  
Despite speculation, there is no published evidence that any of the 50 patients reported to 2014 with 
acetaminophen-associated 5-oxoprolinuric HAGMA had a genetic defect of the γ-glutamyl cycle. GS was 
measured in fibroblasts or red cells in only four and was normal. One also had normal 5-oxoprolinase 
activity (Brohan et al., 2014; Liss et al., 2013; Pitt and Hauser 1998). In addition, we measured red cell GS in 
one of our own patients and found a normal value (not reported). Heterozygotes for inherited GS 
NAPQI inhibition of glutathione synthetase 
 
19 
 
deficiency have GS activity of 55 +/- 13% (mean [SD]) of normal and are asymptomatic (Njålsson et al., 
2005). Inhibition of the activity of a normal GS enzyme by NAPQI could cause 5-oxoprolinuria, but why 
would this only occur in such a small sub-group of the world population who consume acetaminophen? 
We suggest that reduced detoxification of NAPQI resulting from glutathione depletion, and its constant 
production from repeated chronic ingestion of acetaminophen, could increase intracellular NAPQI to levels 
which inhibit GS. This could contribute to 5-oxoprolinuria. 
 
The patients reported were at high risk of glutathione depletion because of a poor intake of cysteine, 
chronic liver disease, or on-going glutathione losses through degradation during sepsis-induced oxidative 
and nitrosative stress, often in combination (Emmett, 2014; Malmezat et al., 2000; Wu et al., 2004). 
Glutathione depletion increases the risk for acetaminophen toxicity (Mitchell et al., 1973). This was shown 
when glutathione synthesis was reduced in γGCS-deficient rats (Akai et al., 2007) and mice (McConnachie 
et al., 2007; Slitt et al. 2005), and in lymphocytes of a human patient with inherited GS deficiency (Spielberg 
and Gordon, 1981). In early studies in mice, covalent binding of NAPQI to proteins did not start until 30-45 
min after exposure to large toxic doses of acetaminophen (≥ 350 mg/kg) which reduced liver glutathione by 
75%. However, this still left a significant amount of glutathione (1 mM) (Mitchell et al., 1973). In more 
recent studies, protein adducts formed within 15 min (Muldrew et al., 2002), and were detectable even 
after non-toxic acetaminophen doses as low as 15 mg/kg, with only a minimal decrease in glutathione 
(McGill et al., 2013). These later studies suggest that NAPQI binding to proteins and glutathione occurs 
simultaneously (and independently) from the onset of NAPQI production, and that severe glutathione 
depletion is not a pre-requisite for protein binding. In fact, protein adducts were detectable in serum of 
healthy adults taking therapeutic doses of acetaminophen (Heard et al., 2011). However, glutathione 
depletion does increase the amount of adduct formed because less glutathione is available to scavenge 
NAPQI (McGill et al., 2013; Mitchell et al., 1973). 
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By releasing γ-GCS from feedback inhibition, glutathione depletion increases γ-glutamylcysteine synthesis. 
Expression and activity of γ-GCS are increased further by oxidative and nitrosative stress, inflammation and 
inflammatory cytokines (Malmezat et al., 2000; Wu et al., 2004). Compared with γ-GCT, GS has a much 
higher activity and affinity for γ-glutamylcysteine. Normally therefore, the flood of increased γ-
glutamylcysteine is directed towards glutathione synthesis to replenish stores (Wu et al., 2004). It could be 
diverted to 5-oxoproline if GS activity was inhibited or over-whelmed. 
In humans who survive an acute acetaminophen overdose, exposure of hepatocytes to NAPQI is curtailed 
rapidly. Data for 5-oxoproline are lacking since organic acid analyses are not part of the routine work-up of 
such patients. However, two (possibly three) of the 50 cases reported with acetaminophen-induced 5-
oxoprolinuria described above had acute acetaminophen toxicity. Hence it is possible that 5-oxoprolinuria 
may occur after acute overdose but resolves and passes undetected. The situation is different in patients 
with low glutathione because of an underlying chronic morbidity. Their glutathione reserves are drained 
constantly by repeated challenge from acetaminophen ingestion. In this chronic situation, NAPQI could 
accumulate when the capacity to replace the glutathione losses becomes inadequate. Continuation of 
acetaminophen, even in therapeutic doses, could then cause toxicity and increase adduct formation.  
In such patients with complex morbidities, other factors, for example accelerated protein catabolism, could 
increase 5-oxoproline production (Figure 1a). Cysteine deficiency arising from an inadequate intake of 
cysteine and its precursor methionine, and urinary losses of sulphated acetaminophen metabolites, could 
also contribute. Cysteine is the rate-limiting substrate for glutathione synthesis. In vitro, incubation of γ-
GCS with L-glutamate without cysteine resulted in production of phosphorylated glutamate which readily 
converted to 5-oxoproline (Orlowski and Meister 1971). Emmett (2014) proposed that through this process 
cysteine depletion, together with increased activity of γ-GCS due to low glutathione levels, would lead to 
accumulation of 5-oxoproline. Demonstration of low hepatocyte concentrations of γ-glutamylcysteine 
would support this proposal, but there are no published data. 
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 Although not investigated, an alternative explanation could be that NAPQI inhibits 5-oxoprolinase. This 
enzyme has essential cysteine residues and is rapidly inactivated by the sulfhydryl group inhibitor, N-
ethylmaleimide (Williamson and Meister, 1982). Acidosis is not a feature of inherited 5-oxoprolinase 
deficiency (Ristoff and Larsson, 2007), but might be provoked by simultaneous GS inhibition or renal failure. 
Other possible explanations for 5-oxoprolinuric acidosis are highly unlikely in the majority of cases. Glycine 
deficiency may contribute to mild 5-oxoprolinuria in children with severe protein-energy malnutrition, but 
deficiency of this non-essential amino is otherwise exceptionally rare (Emmett, 2014). Foods rich in 
glutamine (notably tomato juice) which cyclises to 5-oxoproline are unlikely sources.  Flucloxacillin was 
proposed in one case report (Croal et al., 1998), and listed as a cause since, but this is still unproven. The D-
isomer probably accounts for 5-oxoprolinuria reported during treatment with the γ-aminobutyric acid 
(GABA) antagonist vigabatrin (Larsson et al., 2005).  
Conclusions  
NAPQI binds covalently to GS causing irreversible inhibition of enzyme activity in vitro. These novel 
preliminary findings are the first indication that NAPQI may inhibit glutathione production. This has not 
been explored so far, despite the pivotal role of glutathione in protection against acetaminophen toxicity. 
The biological relevance of GS inhibition should be investigated in cell cultures. The possibility that NAPQI 
may also inhibit other enzymes in the glutathione and supportive methionine transsulphuration pathways 
should be explored. The hypothesis that inhibition of GS by NAPQI could contribute to the development of 
acetaminophen associated 5-oxoprolinuric HAGMA merits further investigation. 
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Appendices 
Appendix 1.  Mass spectra and error plots of fragment ions of the GS peptide modified by NAPQI after co-
incubation of 5 μg of hGS with 15 μg of NAPQI for 60 min at 37 °C. Results for two independent 
experiments. 
Figure 5 
Figure 5a. Mass spectrum of the modified peptide VVQCISELGIFGVYVR (MW = 1989.026) from experiment 
1. NAPQI (∆mass = 149.0477 Da), carboamidomethylation (∆mass = 57.021 Da) and deamidation are isolate 
to fragment ions from y16 to y11 corresponding to the amino acids VVQCI. 
 
Figure 5b. Error plot of fragment ions from the modified peptide VVQCISELGIFGVYVR (MW = 1989.026) 
from experiment 1. NAPQI, carboamidomethylation and deamidation are isolate to fragment ions from y16 
to y11 corresponding to the amino acids VVQCI. 
 
Figure 5c. Mass spectrum of the modified peptide VVQCISELGIFGVYVR (MW = 1989.026) from experiment 
2. NAPQI, carboamidomethylation and deamidation are isolate to fragment ions from y16 to y10 
corresponding to the amino acids VVQCIS. 
 
Figure 5d. Error plot of fragment ions from the modified peptide VVQCISELGIFGVYVR (MW = 1989.026) 
from experiment 2. NAPQI, carboamidomethylation and deamidation are isolate to fragment ions from y16 
to y10 corresponding to the amino acids VVQCI. 
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Appendix 2.  Inhibition of activity of GS (81 mg/L; 0.77 μM) pre-incubated with NAPQI (0-100 μM) for 30 
min at 37 ºC. Enzyme activity was measured by the described procedure, with GAB substrate 
concentrations 2.5 mM and 10.0 mM.  NAP = NAPQI; concentrations 0-100 μM.                                
Figure 6a. GS activity, reported as μmol of NADH oxidized in the reporter reaction/min/mg of GS. 
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Figure 6b. Time course of GS activity after 30 min of preincubation with NAPQI. GS activity was monitored 
at 28 s intervals for 168 s under standard assay conditions with 10 mM GAB as substrate. Activity reported 
as μmol of NADH oxidized/mg of GS. 
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